Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Provided By GlobeNewswire

Last update: Nov 5, 2024

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity